Abbott Laboratories (ABT)
| Market Cap | 230.98B |
| Revenue (ttm) | 41.95B |
| Net Income (ttm) | 13.40B |
| Shares Out | 1.73B |
| EPS (ttm) | 7.64 |
| PE Ratio | 17.43 |
| Forward PE | 25.83 |
| Dividend | $2.36 (1.77%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 3,546,427 |
| Open | 131.73 |
| Previous Close | 132.13 |
| Day's Range | 131.35 - 133.28 |
| 52-Week Range | 99.71 - 133.28 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 131.41 (-1.32%) |
| Earnings Date | Apr 16, 2025 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.40 billion, an increase of 135.08%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $131.41, which is a decrease of -1.32% from the latest price.
News
Here are the best performing dividend aristocrats stocks in 2025
Dividend aristocrat stocks have largely done well in the past few years. The closely-followed ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has jumped by over 133% from its lowest level in 2020.
Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care
New survey shows 40% of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma1 70% of people with diabetes said supportive comments from others can significa...
My Best Dividend Aristocrats For February 2025
The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the...
Is There More Upside For ABT Stock After A 10% Jump In A Week?
Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 o...
Abbott Laboratories: Strong Q4 Results And Bullish Outlook
On January 22, Abbott Laboratories published financial results for the fourth quarter of 2024, initially receiving mixed reactions from Wall Street. However, its revenue was about $10.97 billion for t...
What Can The Dividend Kings Deliver In 2025?
The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by ea...
Why Is Abbott Stock Trading Higher On Thursday?
On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
Two Contrarian Dividends With Triple-Digit Potential For Trump 2.0
Tariff Day has left us with Canada and Mexico in the crosshairs. With North American trade in focus, this may actually give a respite to stocks with supply chains elsewhere and light a fire under them...
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month. The company looks set up to deliver double-digit annual adjusted diluted E...
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday.
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Conference Call January 22, 2025 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman & Chief Execu...
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates
Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.
Abbott forecasts in line annual profit on medical device sales
Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitor...
Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 p...
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di...
Long-term possibilities in healthcare are unbelievable, says Jim Cramer
'Mad Money' host Jim Cramer looks at several healthcare stocks and shares his perspective on their trajectory in 2025.
Abbott Laboratories Q4 2024 Earnings Preview
Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. Abbott continues to execute growth businesses with excellent marketing and distributio...
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens.
My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks
I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is...
Highest Quality Dividend Kings For 2025
Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation ...
DexCom, Abbott Agree to Settlement in Patent Litigation
The companies have been involved in global patent litigation, with both having accused the other of infringing certain patents, and each has filed counterclaims and actions to invalidate the other par...
Abbott and DexCom settle glucose monitor patent disputes
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.